Partex

Partex.AI – The world’s largest AI-powered therapeutic asset accelerator. Our vision is to address inefficiencies in drug discovery & development using AI at scale, bringing discovered drug candidates faster to right patients efficiently. Our services accelerate the data-scrutinizing process, empowering pharma and biotech companies to speed up their progress in drug discovery and development. What we do: Therapeutics: Identification of late-stage preclinical and early clinical assets with strong science but limited development paths. AI models refine and advance these therapies toward key value milestones. Currently incubating three oncology assets through dedicated SPVs. Drug Asset Exchange: AI-enabled platform for pharma and biotech to evaluate, reposition, and transact deprioritized or off-strategy assets. Supports efficient pipeline optimization through flexible, data-backed collaboration models. Labs: Integration of advanced functional assays with high-throughput screening to validate AI predictions. A closed-loop framework that combines computational modeling with experimental biology to deliver robust, disease-relevant evidence. Real-World Data: Global partnerships with healthcare providers to unlock Real-World Data for drug development and treatment optimization. Enabling data-driven insights that support better outcomes and smarter clinical decision-making. CEO & Co-Founder: Dr. Gunjan Bhardwaj Chairman & Co-Founder: Francisco Fernandez Companies belonging to Partex group: Partex.AI Switzerland Partex.AI Labs Partex.AI Therapeutics Headquarters Eschborn, Hessen